| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2025 , Vol 63 , Num 3
Development and validation of a versatile ultra performance liquid chromatography method for simultaneous estimation of selected antiviral drugs in bulk and dosage form
1 Department of Pharmaceutical Analysis, Aditya College of Pharmacy, ADB road, Surampalem-533437, India2 Department of Pharmaceutical Analysis, Hindu College of Pharmacy, Amaravathi Road, Guntur-522002, India
DOI : 10.23893/1307-2080.APS6339 Viewed : 2407 - Downloaded : 1225 This research aimed to develop and validate an accurate Ultra performance Liquid Chromatography (UPLC) method with Photo Diode Array detection to simultaneously estimate Bictegravir, Emtricitabine and Tenofovir Alafenamide Fumarate in their fixed dose combination. The developed method used Acetonitrile and pH 2.5 triethanolamine buffer in a 30:70 v/v ratio as the mobile phase at 1.0 mL/min flow rate and 0.50 ?L injection volume. The analytes were separated on a BEH C18 column (1.8?, 100×2.1mm) and detected at 265nm. Bictegravir, Emtricitabine and Tenofovir Alafenamide Fumarate obeyed Beer"s law in the ranges of 5?75 ?g/mL, 20-300 ?g/mL and 2.50?37.50 ?g/mL respectively. The recovery for accuracy was 99-101%. Precision and robustness met acceptable limits. This stability indicating method could distinguish and quantify the compounds even with degradants. Thus, a specific, accurate and robust stability indicating method was developed to simultaneously quantify Bictegravir, Emtricitabine and Tenofovir Alafenamide fumarate in their combined dosage form. Keywords : bictegravir, emtricitabine, tenofovir alafenamide fumarate, UPLC